Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Genitourinary 1

Conditions

Prostatic Neoplasms 5024Carcinoma, Renal Cell 1577Urinary Bladder Neoplasms 1279Kidney Neoplasms 724Breast Neoplasms 643Neoplasms 630Carcinoma, Transitional Cell 488Carcinoma, Non-Small-Cell Lung 469Neoplasm Metastasis 468Melanoma 421Ovarian Neoplasms 401Colorectal Neoplasms 373Lung Neoplasms 333Pancreatic Neoplasms 262Sarcoma 232Stomach Neoplasms 227Uterine Cervical Neoplasms 225Testicular Neoplasms 216Non-Muscle Invasive Bladder Neoplasms 215Head and Neck Neoplasms 192Squamous Cell Carcinoma of Head and Neck 189Colonic Neoplasms 167Carcinoma, Hepatocellular 167Esophageal Neoplasms 165Endometrial Neoplasms 165Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 130Small Cell Lung Carcinoma 127Neuroblastoma 127

Interventions

enfortumab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Urothelial Cancer and Other Malignant Solid Tumors × Genitourinary × Clear all
NCT02091999 2024-11-01

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Astellas Pharma Inc

Phase 1 Completed
213 enrolled
GenitourinaryOther solid neoplasm

Metastatic Urothelial Cancer and Other Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡